Chance Pharmaceuticals
PrivateLast Round
IPO
Oct 8, 2025
Est. Valuation
$779.1M
Total Funding Raised
$257.86M
Company Overview
Chance Pharmaceuticals is a clinical-stage biotechnology company that specializes in the discovery, development, and commercialization of innovative dry powder inhalation (DPI) therapies for respiratory, central nervous system, and fibrotic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical Devices, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Chance Pharmaceuticals Comparables
Compare Chance Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Zhejiang Xina Pharmaceutical Co., Ltd. | 78% | |
| Suzhou Inhal Pharma Co., Ltd. | 77% | |
| Transpire Bio Inc. | 77% |
Chance Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Oct 8, 2025 | ||||
| VC Round | Mar 17, 2025 | ||||
| Series C Extension | Jan 4, 2022 | ||||
| Series C | Oct 11, 2021 | ||||
| Series F | Jul 2, 2020 | ||||
Series E | Jan 2, 2020 |
Chance Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BioTrack Capital | Series F |
| Longmen Capital | Series D |
| Oriza Holdings | Series E |
| 招银国际金融有限公司 | IPO |
| SDIC Innovation Investment Management | Series D |
| China Merchants Securities | Series C |
| Lapam Capital | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 20, 2026
Monthly visitors increased 66% MoM.
- Jul 2, 2020
$52M round led by Zhongjin Qichen and BioTrack Capital.
Chance Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Chance Pharmaceuticals's valuation, stock price, and market status.
Is Chance Pharmaceuticals a public or private company?
Chance Pharmaceuticals is a private company.
What is the current stock price of Chance Pharmaceuticals?
Chance Pharmaceuticals is a private company with no public stock price. No recent secondary market data is available.
How much is Chance Pharmaceuticals worth (valuation)?
Valuation information for Chance Pharmaceuticals is not publicly available.
Can I buy Chance Pharmaceuticals stock?
Chance Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Chance Pharmaceuticals's last funding round?
Chance Pharmaceuticals's most recent funding round was VC Round on March 17, 2025.
Who are the main investors in Chance Pharmaceuticals?
Key investors in Chance Pharmaceuticals include Lapam Capital, Shenzhen Dachen Caizhi Venture Capital Management.
Will Chance Pharmaceuticals IPO soon?
No public IPO plans have been announced for Chance Pharmaceuticals.
How can I track Chance Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Chance Pharmaceuticals's secondary market activity and sign up for updates.